Cantor Fitzgerald Reiterates Overweight on Ambrx Biopharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Ambrx Biopharma (NASDAQ:AMAM) and maintained a $25 price target.
October 23, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ambrx Biopharma and maintained a $25 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ambrx Biopharma. The maintained price target of $25 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100